FHA
DFTX

Flagship Harbor Advisors’s Definium Therapeutics DFTX Stock Holding History

Flagship Harbor Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,721
Closed -$117K – 1615
2025
Q4 		$117K Buy
+8,721
New +$108K 0.01% 827

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Harbor Advisors's DFTX Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 8,721 shares — an estimated $117K sold.

Flagship Harbor Advisors first reported a position in DFTX in Q4 2025 and held it in 1 quarter. The position peaked at $117K in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 8,721 Definium Therapeutics shares in Q1 2026, an estimated $117K.
  • Flagship Harbor Advisors first reported a position in Definium Therapeutics in Q4 2025 and held it in 1 quarter.
  • Flagship Harbor Advisors's Definium Therapeutics position peaked at $117K in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.